Suppr超能文献

血管加压素在感染性休克中血管收缩作用的异质性。

Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock.

作者信息

Malay Mary-Beth, Ashton Jennifer L, Dahl Katherine, Savage Edward B, Burchell Sherryl A, Ashton Robert C, Sciacca Robert R, Oliver Juan A, Landry Donald W

机构信息

Allegheny University of the Health Sciences, Allegheny General Hospital, Division of General Surgery, Pittsburgh, PA, USA.

出版信息

Crit Care Med. 2004 Jun;32(6):1327-31. doi: 10.1097/01.ccm.0000128578.37822.f1.

Abstract

OBJECTIVE

To determine whether pressor doses of vasopressin impair organ blood flow in endotoxic shock.

DESIGN

Graded doses of vasopressin or phenylephrine, starting at the clinically recommended doses for pressure support in septic shock, were intravenously infused during endotoxic shock.

SETTING

University hospital surgical research laboratory.

SUBJECTS

Twelve random-bred female Yorkshire pigs.

INTERVENTIONS

We measured mean arterial pressure, cardiac output, heart rate, pulmonary artery occlusion pressure, and carotid, mesenteric, renal, and iliac blood flows.

MEASUREMENTS AND MAIN RESULTS

Low doses of vasopressin (typically used in the clinical management of septic shock) raised arterial pressure by increasing systemic vascular resistance without a significant preferential effect in the circulations measured. However, moderately greater doses of vasopressin had a very heterogeneous vasoconstrictor action; although there was no significant vasoconstriction in the carotid and iliac circulations, mesenteric and renal blood flows decreased markedly. Furthermore, at pressor doses vasopressin improved cerebral perfusion.

CONCLUSIONS

The vasoconstrictor action of exogenous low-dose vasopressin in endotoxic shock does not impair blood flow to any of the vascular beds examined. However, moderately higher doses of vasopressin may induce ischemia in the mesenteric and renal circulations. The data indicate that the safe dose range for exogenous vasopressin in septic shock is narrow and support the current practice of fixed low-dose administration, generally 0.04 units/min and in no case exceeding 0.1 units/min.

摘要

目的

确定升压剂量的血管加压素是否会损害内毒素性休克时的器官血流。

设计

在内毒素性休克期间,静脉输注血管加压素或去氧肾上腺素的分级剂量,起始剂量为脓毒性休克时临床上推荐的压力支持剂量。

地点

大学医院外科研究实验室。

对象

12只随机繁殖的雌性约克夏猪。

干预措施

我们测量了平均动脉压、心输出量、心率、肺动脉闭塞压以及颈动脉、肠系膜、肾和髂动脉血流。

测量指标及主要结果

低剂量血管加压素(通常用于脓毒性休克的临床治疗)通过增加全身血管阻力来升高动脉压,在所测量的循环系统中未产生显著的优先效应。然而,稍大剂量的血管加压素具有非常不均匀的血管收缩作用;尽管颈动脉和髂动脉循环中没有明显的血管收缩,但肠系膜和肾血流明显减少。此外,在升压剂量下,血管加压素可改善脑灌注。

结论

外源性低剂量血管加压素在内毒素性休克中的血管收缩作用不会损害所检查的任何血管床的血流。然而,稍高剂量的血管加压素可能会导致肠系膜和肾循环缺血。数据表明,脓毒性休克中外源性血管加压素的安全剂量范围很窄,支持目前固定低剂量给药的做法,一般为0.04单位/分钟,且绝不超过0.1单位/分钟。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验